Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance

AbbVie IncTrade
YieldMax AMZN Option Income Strategy ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $248.89 (market cap $438.19B), while YieldMax AMZN Option Income Strategy ETF trades at $11.42. The key difference: AbbVie Inc pays a 2.79% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

ABBVAMZY
Market Cap
$438.19B
Sector
HealthIncome / Options Overlay
52-Week High
$263.58$15.75
52-Week Low
$197.38$9.98
Enterprise Value
$502.45B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $11.54, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions, though analyst reports express concerns over potential net asset value erosion despite the high yield strategy.

The outlook is mixed; the high-yield dividend strategy attracts income investors, but fundamental risks include underperformance versus Amazon and sustainability of payouts. Key risks involve amplified downside exposure and competitive pressures, warranting cautious evaluation for long-term growth-oriented investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY